STANFORD, October 2 — A Stanford Medicine-led clinical trial published in Scientific Reports on September 30, 2026, found that acebilustat, an experimental oral drug targeting leukotriene B4 production, alleviated burdensome symptoms of lower limb lymphedema in 23 participants over one year. The trial was led by Dr. Stanley Rockson, the Allan and Tina Neill Professor in Lymphatic Research and Medicine at Stanford Medicine.
Participant Matthew Holbreich, who works for a clinical trial software company and has lived with lymphedema for over two decades, reported significant improvement after years of relying on daily compression stockings and biannual intensive physical treatments involving lymphatic massage and heavy wrapping. He had previously experienced two infection-related hospitalizations due to the condition.
Rockson noted that current standard treatments — compression garments, physical therapy, and compression machines — typically achieve at most a 50% reduction in disease severity and are often less effective, labor-intensive, and costly, with insurance frequently not covering full expenses. He emphasized that lymphedema affects an estimated 10 million people in the United States and likely hundreds of millions globally, with higher prevalence in women due to shared risk factors like breast cancer.
The condition can result from cancer treatments such as radiation or surgery for breast or gynecologic cancers, as well as obesity, heart failure, sleep apnea, venous hypertension, or genetic factors. Rockson’s earlier research identified the 5-lipoxygenase (5-LO) pathway’s role in lymphedema, including prior trials with ketoprofen, which showed symptom relief but carried long-term heart disease risks.
Those risks prompted the search for safer alternatives, leading to the development of acebilustat, which more specifically inhibits LTB4 production compared to the broader action of ketoprofen. The drug represents a more targeted approach within the same biochemical pathway. No specific financial figures, drug pricing, market impact, or investment details were disclosed in the source material regarding the economic or financial implications of the research or potential commercialization of acebilustat.
The study did not report on insurance coverage prospects, out-of-pocket costs for patients, or potential reimbursement challenges should the drug advance toward regulatory approval. As of the reporting date, the drug remains investigational, with no indication of FDA submission timelines or commercialization plans disclosed. Researchers continue to monitor long-term safety and efficacy beyond the one-year trial period.
The next steps will likely involve larger Phase III trials to confirm these findings across a more diverse patient population and to assess sustained symptom control and safety over extended use. Until then, patients like Holbreich remain dependent on existing therapies that, while helpful, fall short of addressing the full burden of the disease.
